The current role of radiotherapy in the treatment of small cell lung cancer.
Affiliation
The Christie Hospital NHS Foundation Trust, Manchester, UKIssue Date
2016-08-10
Metadata
Show full item recordAbstract
Radiotherapy has been shown to play a key role in the management of small cell lung cancer. There are well-established data in the literature for the use of concurrent chemoradiotherapy for stage I-III disease, although key questions remain over the timing of radiation, the optimal dose/fractionation and particularly once versus twice daily treatment, the use of elective nodal irradiation and drug combinations. Data for the use of thoracic radiation in stage IV disease, after chemotherapy, have recently become available and are leading to a change in practice. Prophylactic cranial irradiation has been shown to be of use in both stage I-III and stage IV disease, although uncertainties surround its use in the elderly population and the use of brain imaging before treatment. This overview will address the current available evidence and focus on areas for future research.Citation
The current role of radiotherapy in the treatment of small cell lung cancer. 2016: Clin OncolJournal
Clinical OncologyDOI
10.1016/j.clon.2016.07.012PubMed ID
27522475Type
ArticleLanguage
enISSN
1433-2981ae974a485f413a2113503eed53cd6c53
10.1016/j.clon.2016.07.012
Scopus Count
Collections
Related articles
- Radiotherapy for small-cell lung cancer-Where are we heading?
- Authors: Bayman NA, Sheikh H, Kularatne B, Lorigan P, Blackhall F, Thatcher N, Faivre-Finn C
- Issue date: 2009 Mar
- High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial.
- Authors: Grønberg BH, Killingberg KT, Fløtten Ø, Brustugun OT, Hornslien K, Madebo T, Langer SW, Schytte T, Nyman J, Risum S, Tsakonas G, Engleson J, Halvorsen TO
- Issue date: 2021 Mar
- Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
- Authors: Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, Bezjak A, Cardenal F, Fournel P, Harden S, Le Pechoux C, McMenemin R, Mohammed N, O'Brien M, Pantarotto J, Surmont V, Van Meerbeeck JP, Woll PJ, Lorigan P, Blackhall F, CONVERT Study Team
- Issue date: 2017 Aug
- Clinical outcomes of extensive-stage small cell lung cancer patients treated with thoracic radiotherapy at different times and fractionations.
- Authors: Han J, Fu C, Li B
- Issue date: 2021 Mar 4
- Effects of thoracic radiotherapy timing and duration on progression-free survival in limited-stage small cell lung cancer.
- Authors: Zhao S, Zhou T, Ma S, Zhao Y, Zhan J, Fang W, Yang Y, Hou X, Zhang Z, Chen G, Zhang Y, Huang Y, Zhang L
- Issue date: 2018 Sep